These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38719498)

  • 1. Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis.
    Nassiri S; Van de Bovenkamp AA; Remmelzwaal S; Sorea O; de Man F; Handoko ML
    Open Heart; 2024 May; 11(1):. PubMed ID: 38719498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study.
    Gunes Y; Guntekin U; Tuncer M; Sahin M
    Heart Vessels; 2009 Jul; 24(4):277-82. PubMed ID: 19626400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A
    J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis.
    Wen J; Ma X; Zhang L; Lu X; Yang Y; Wang J; Zhao Y
    Medicine (Baltimore); 2018 Dec; 97(51):e13580. PubMed ID: 30572460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is treatment with trimetazidine beneficial in patients with chronic heart failure?
    Zhou X; Chen J
    PLoS One; 2014; 9(5):e94660. PubMed ID: 24797235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.
    Coats CJ; Pavlou M; Watkinson OT; Protonotarios A; Moss L; Hyland R; Rantell K; Pantazis AA; Tome M; McKenna WJ; Frenneaux MP; Omar R; Elliott PM
    JAMA Cardiol; 2019 Mar; 4(3):230-235. PubMed ID: 30725091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
    Gao D; Ning N; Niu X; Hao G; Meng Z
    Heart; 2011 Feb; 97(4):278-86. PubMed ID: 21134903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial.
    van de Bovenkamp AA; Geurkink KTJ; Oosterveer FTP; de Man FS; Kok WEM; Bronzwaer PNA; Allaart CP; Nederveen AJ; van Rossum AC; Bakermans AJ; Handoko ML
    ESC Heart Fail; 2023 Oct; 10(5):2998-3010. PubMed ID: 37530098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exercise-based rehabilitation for heart failure.
    Taylor RS; Sagar VA; Davies EJ; Briscoe S; Coats AJ; Dalal H; Lough F; Rees K; Singh S
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD003331. PubMed ID: 24771460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
    Abdul-Rahim AH; Shen L; Rush CJ; Jhund PS; Lees KR; McMurray JJV;
    Eur J Heart Fail; 2018 Jul; 20(7):1139-1145. PubMed ID: 29493058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose versus low-dose angiotensin converting enzyme inhibitors in heart failure: systematic review and meta-analysis.
    Migliavaca CB; Stein C; Colpani V; Eibel B; Bgeginski R; Simões MV; Rohde LE; Falavigna M
    Open Heart; 2020 Aug; 7(2):. PubMed ID: 32820054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of trimetazidine in management of ischemic cardiomyopathy.
    Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
    Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of trimetazidine in non-ischemic heart failure patients: a meta-analysis of randomized controlled trials.
    Zhao C; Jin C; He X; Xiang M
    Rev Cardiovasc Med; 2021 Dec; 22(4):1451-1459. PubMed ID: 34957784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of trimetazidine in patients with severe chronic heart failure with reduced left ventricular ejection fraction: A prospective, randomized, open-label, cross-over study.
    Bohdan M; Stopczyńska I; Wiśniewski P; Moryś J; Niedoszytko P; Gruchała M
    Cardiol J; 2022; 29(4):627-636. PubMed ID: 33200813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
    Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
    Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
    Kapelios CJ; Murrow JR; Nührenberg TG; Montoro Lopez MN
    Heart Fail Rev; 2019 May; 24(3):367-377. PubMed ID: 30618017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
    JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.